Purpose A prior study demonstrated that addition of continuous daily erlotinib fails to
improve response rate or survival in non–small-cell lung cancer (NSCLC) patients treated …

Purpose This study investigated whether sequential administration of erlotinib and
chemotherapy improves clinical outcomes versus chemotherapy alone in unselected …

BACKGROUND. Preclinical studies have suggested that erlotinib at high doses may inhibit
additional sites downstream of the epidermal growth factor receptor (EGFR), resulting in …

Background Erlotinib and pemetrexed have been approved for the second-line treatment of
non-small cell lung cancer (NSCLC). These two agents have different mechanisms of action …

8031 Background: Concurrent administration of EGFR TKIs and chemotherapy in 1st line
failed to improve survival. Preclinical data suggested potential antagonism due to TKI …

Background Concomitant administration of erlotinib with standard chemotherapy does not
appear to improve survival among patients with non-small-cell lung cancer (NSCLC), but …

Purpose Erlotinib is a potent reversible HER1/epidermal growth factor receptor (EGFR)
tyrosine kinase inhibitor with single-agent activity in patients with non–small-cell lung cancer …

Purpose Erlotinib is clinically effective in patients with non–small-cell lung cancer (NSCLC)
who have adenocarcinoma, are never or limited former smokers, or have EGFR mutant …

7022 Background: In phase II studies, erlotinib has shown single agent activity in a number
of tumor types, including NSCLC. NCIC CTG BR. 21 is a randomized, placebo-controlled …

BACKGROUND. Erlotinib is an orally available, reversible inhibitor of epidermal growth
factor receptor (EGFR) with a proven survival advantage for patients with locally advanced …